Ⅳ期男性乳腺癌一线内分泌解救治疗一例

郭美琴; 宋伟

doi:10.3877/cma.j.issn.1674-0807.2023.02.011

中华乳腺病杂志(电子版) >

2023 , Vol. 17 >Issue 02: 119 - 121

DOI: https://doi.org/10.3877/cma.j.issn.1674-0807.2023.02.011

病例报告

Ⅳ期男性乳腺癌一线内分泌解救治疗一例

郭美琴 ^,^† ,
宋伟

展开

030001　太原，山西医科大学第二医院乳腺外科

通信作者：郭美琴，Email：mqg_0355@163.com

收稿日期: 2022-11-04

网络出版日期: 2023-06-27

版权

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计，除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。本刊为电子期刊，以网刊形式出版。

收起

First line endocrine rescue treatment for stage Ⅳ male breast cancer: one case report

Meiqin Guo ^,^† ,
Wei Song

Expand

Received date: 2022-11-04

Online published: 2023-06-27

Copyright

No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.

All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.

Fold

摘要

男性乳腺癌发病罕见，在乳腺癌中占比约1%，占所有男性癌症的1%^[1]，但近年来其发病率有所上升^[2]。目前，该病的诊治多参照女性乳腺癌。笔者报道了1例接受一线内分泌解救治疗的Ⅳ期男性乳腺癌患者，治疗效果较好，以期为这类患者的诊治提供临床依据。

关键词： 乳腺肿瘤; 男人; 内分泌治疗

本文引用格式

郭美琴 , 宋伟 . Ⅳ期男性乳腺癌一线内分泌解救治疗一例[J]. 中华乳腺病杂志(电子版), 2023 , 17(02) : 119 -121 . DOI: 10.3877/cma.j.issn.1674-0807.2023.02.011

参考文献

原文顺序 | 文献年度倒序 | 文中引用次数倒序

[1]	Contractor KB, Kaur K, Rodrigues GS, et al. Male breast cancer: is the scenario changing[J]. World J Surg Oncol, 2008，6：58.

[2]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34.

[3]	Hassett MJ, Somerfield MR, Baker ER, et al. Management of male breast cancer: ASCO guideline[J]. J Clin Oncol, 2020，38(16)：1849-1863.

[4]	申戈，宋三泰，江泽飞，等. 睾丸切除加来曲唑治疗晚期男性乳腺癌一例[J]. 中华医学杂志，2004, 84(3)：29.

[5]	Eggemann H, Altmann U, Costa SD, et al. Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients[J]. Breast Cancer Res Treat，2013，137(2)：465-470.

[6]	Mauras N, O’Brien KO, Klein KO, et al. Estrogen suppression in males: metabolic effects[J]. J Clin Endocrinol Metab, 2000, 85(7)：2370-2377.

[7]	Bighin C, Lunardi G, Del Mastro L, et al. Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors[J]. Oncologist, 2010, 15(12)：1270-1272.

[8]	Zagouri F, Sergentanis TN, Azim HA Jr, et al. Aromatase inhibitors in male breast cancer：a pooled analysis[J]. Breast Cancer Res Treat, 2015, 151(1)：141-147.

[9]	国家肿瘤质控中心乳腺癌专家委员会，中国抗癌协会乳腺癌专业委员会，中国抗癌协会肿瘤药物临床研究专业委员会．中国晚期乳腺癌规范诊疗指南(2020版)[J]. 中华肿瘤杂志，2020，42(10)：781-797.

[10]	U．S. Food and Drug Administration. U．S. FDA approves IBRANCE? (palbociclib) for the treatment of men with HR+，HER2- metastatic breast cancer[EB/OL]．[2022-11-01]．

[11]	Morisseau C, Pakhomova S, Hwang SH, et al. Inhibition of soluble epoxide hydrolase by fulvestrant and sulfoxides[J]. Bioorg Med Chem Lett, 2013, 23(13)：3818-3821.

[12]	Zagouri F, Sergentanis TN, Chrysikos D, et al. Fulvestrant and male breast cancer: a pooled analysis[J]. Breast Cancer Res Treat, 2015, 149(1)：269-275.

[13]	Hansra D, Jackson S, Sequeira J, et al. Male patient with metastatic stage breast cancer chieves complete remission on second line abemaciclib, fulvestrant and leuprolide: a case report[J]. Mol Clin Oncol, 2020, 12(2)：120-125.

[14]	Tripathy D, Blum JL, Rocque GB, et al. POLARIS: a prospective, multicenter, noninterventional study assessing palbociclib in hormone receptor positive advanced breast cancer[J]. Future Oncol, 2020, 16(31)：2475-2485.

Options

文章导航

模态框（Modal）标题

摘要

本文引用格式

参考文献